Log in
Enquire now
‌

US Patent 10179131 Hepatitis B antiviral agents

Patent 10179131 was granted and assigned to Enanta Pharmaceuticals on January, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Current Assignee
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10179131
Date of Patent
January 15, 2019
Patent Application Number
15209150
Date Filed
July 13, 2016
Patent Citations Received
0
‌
US Patent 11891393 Functionalized heterocycles as antiviral agents
0
‌
US Patent 12011425 Hepatitis B antiviral agents
0
‌
US Patent 11472808 Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
‌
US Patent 10538532 Hepatitis B antiviral agents
‌
US Patent 11236108 Functionalized heterocycles as antiviral agents
‌
US Patent 11236111 Hepatitis B antiviral agents
‌
US Patent 10640511 Hepatitis B antiviral agents
...
Patent Primary Examiner
‌
Alexander R Pagano
Patent abstract

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10179131 Hepatitis B antiviral agents

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.